The association between steatotic liver disease and chronic kidney disease: a meta-analysis and Mendelian randomization study highlighting metabolic comorbidities - PubMed
5 hours ago
- #chronic kidney disease
- #metabolic dysfunction
- #steatotic liver disease
- Steatotic liver disease (SLD) includes NAFLD, MAFLD, and MASLD and is associated with chronic kidney disease (CKD).
- Meta-analysis of 34 studies (3,783,136 participants) shows significant associations between SLD (MAFLD, NAFLD, MASLD) and increased CKD risk.
- Mendelian randomization (MR) analysis found no causal effect of SLD on CKD but identified metabolic factors (BMI, diabetes, blood pressure, lipids) as significant CKD risk drivers.
- Metabolic dysfunction, rather than SLD itself, may be the primary contributor to CKD risk.
- Early screening and intervention for metabolic health in SLD patients are crucial to reduce CKD burden.